Marimastat

Marimastat
Systematic (IUPAC) name
N-[2,2-dimethyl-1- (methylcarbamoyl)propyl]-2- [hydroxy-(hydroxycarbamoyl)methyl]- 4- methyl-pentanamide
Clinical data
Pregnancy cat.  ?
Legal status  ?
Routes oral
Identifiers
CAS number 154039-60-8 Y
ATC code None
PubChem CID 119031
DrugBank APRD00559
ChemSpider 106358 N
UNII D5EQV23TDS N
ChEMBL CHEMBL279785 N
Chemical data
Formula C15H29N3O5 
Mol. mass 331.408 g/mol
 N(what is this?)  (verify)

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.[1][2]

Marimastat performed poorly in clinical trials,[3] and development was terminated.

References

  1. ^ "Marimastat". National Cancer Institute. http://www.cancer.gov/drugdictionary/?CdrID=42443. 
  2. ^ Millar, AW; Brown PD, Moore J, et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol 45: 21–6. PMID 9489589. 
  3. ^ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol 22 (23): 4683–90. PMID 15570070.